Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000289 · ClinicalTrials.gov registry record · Phase 2
Role of Metabolites in Nicotine Dependence (3) - 6
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00000289: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000289 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000289, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
Interventions
- DRUG Ondansetron
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
What the finished NCT00000289 record still lists
NCT00000289 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ondansetron is the first listed.
NCT00000289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000289 about?
NCT00000289 is a clinical study titled "Role of Metabolites in Nicotine Dependence (3) - 6". The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
What is the current status of trial NCT00000289?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-05. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00000289?
The interventions under investigation include: Ondansetron (DRUG).
Who is sponsoring clinical trial NCT00000289?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia